Atyr Pharma Inc (ATYR) recent activity suggests a positive outlook with the last week’s performance of 17.63%

Atyr Pharma Inc (NASDAQ: ATYR) on Friday, soared 5.05% from the previous trading day, before settling in for the closing price of $4.26. Within the past 52 weeks, ATYR’s price has moved between $1.42 and $4.66.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

A company in the Healthcare sector has dropped its sales by -11.05% annually for the last half of the decade. The company achieved an average annual earnings per share of 23.15%. With a float of $86.06 million, this company’s outstanding shares have now reached $89.00 million.

In an organization with 59 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.

Atyr Pharma Inc (ATYR) Insider and Institutional Ownership

Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Atyr Pharma Inc is 3.31%, while institutional ownership is 69.43%. The most recent insider transaction that took place on Mar 17 ’25, was worth 15,000. In this transaction Director of this company bought 3,750 shares at a rate of $4.00, taking the stock ownership to the 9,750 shares. Before that another transaction happened on Feb 04 ’25, when Company’s Chief Financial Officer sold 1,254 for $3.78, making the entire transaction worth $4,740. This insider now owns 31,763 shares in total.

Atyr Pharma Inc (ATYR) Latest Financial update

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.15 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 23.15% per share during the next fiscal year.

Atyr Pharma Inc (NASDAQ: ATYR) Trading Performance Indicators

Atyr Pharma Inc (ATYR) is currently performing well based on its current performance indicators. A quick ratio of 7.79 was reported for the most recent quarter.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.81, a number that is poised to hit -0.18 in the next quarter and is forecasted to reach -0.57 in one year’s time.

Technical Analysis of Atyr Pharma Inc (ATYR)

Let’s dig in a bit further. During the last 5-days, its volume was 1.81 million. That was better than the volume of 1.34 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 91.29%. Additionally, its Average True Range was 0.29.

During the past 100 days, Atyr Pharma Inc’s (ATYR) raw stochastic average was set at 91.95%, which indicates a significant decrease from 97.39% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.07% in the past 14 days, which was lower than the 86.19% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $3.33, while its 200-day Moving Average is $3.07. However, in the short run, Atyr Pharma Inc’s stock first resistance to watch stands at $4.60. Second resistance stands at $4.73. The third major resistance level sits at $4.95. If the price goes on to break the first support level at $4.25, it is likely to go to the next support level at $4.03. The third support level lies at $3.90 if the price breaches the second support level.

Atyr Pharma Inc (NASDAQ: ATYR) Key Stats

Market capitalization of the company is 397.85 million based on 89,004K outstanding shares. Right now, sales total 240 K and income totals -64,020 K. The company made 0 K in profit during its latest quarter, and -14,880 K in sales during its previous quarter.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.